Program
MODAG-009
A development code. Also written as “[¹⁸F]MODAG-009 PET imaging” and “[¹⁸F]MODAG-009 PET Imaging”.
Its studies are mostly in Multiple System Atrophy, led by MODAG.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MODAG | 22 open or running | early phase 1since May 7, 2026 | May 7, 2026 | May 2027early phase 1 · NCT07640555 |
Also a collaborator on its studies: XingImaging.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 7, 2026First studies: 2 early phase 1 studies in Multiple System AtrophyFirst studyNCT07640555, NCT07617688
Ahead
- May 2027Primary completion: early phase 1 study in Multiple System AtrophyNCT07617688
- May 2027Primary completion: early phase 1 study in Multiple System AtrophyNCT07640555
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07617688Multiple System Atrophy · United States | Early 1 | Recruiting | May 2027 | 6 |
| NCT07640555Multiple System Atrophy · United States | Early 1 | Recruiting | May 2027 | 13 |
How it is read
Names in the registry
- “[¹⁸F]MODAG-009 PET imaging”, 1 entry
- “[¹⁸F]MODAG-009 PET Imaging”, 1 entry
Codes read as this program: MODAG009.
Conditions, from the studies’ own filings
- Multiple System Atrophy, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.